.After antibody-drug conjugate (ADC) expert Seagen was offered to Pfizer in 2014 for a monstrous $43...
.On the heels of a stage 3 win that stopped working to make an impression on entrepreneurs, Ironwood...
.Don't quit Monte Rosa Therapeutics currently. The Boston-based biotech is actually enjoying after s...
.Invite to this week's Chutes & Ladders, our summary of notable leadership hirings, firings and a...
.Commemorating his business's upsized going public (IPO), Septerna chief executive officer Jeffrey F...
.AbbVie has gone back to the resource of its own antipsychotic giant Vraylar looking for one more bl...
.GenSight Biologics is weeks far from lacking money. Again. The biotech simply has enough money to f...
.Monopar Therapeutics is actually bouncing back a medicine coming from the scrap heap of AstraZeneca...
.Along with brand-new information out on Arcus Biosciences' experimental HIF-2a inhibitor, one group...
.After forming a genetics treatment partnership with Dyno Rehabs in 2020, Roche is back for more.In ...